Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models

about

Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models

Item

http://www.wikidata.org/entity/Q58708797

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models

@en

Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models

@nl

type

Item

label

Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models

@en

Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models

@nl

prefLabel

Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models

@en

Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models

@nl

P1476

Characterization of Precursor-Dependent Steroidogenesis in Human Prostate Cancer Models

@en

P2093

Antonio Hurtado-Coll

http://www.w3.org/2001/XMLSchema#string

Dong-Sheng Ming

http://www.w3.org/2001/XMLSchema#string

Emma S Tomlinson Guns

http://www.w3.org/2001/XMLSchema#string

Hans Adomat

http://www.w3.org/2001/XMLSchema#string

Martin E Gleave

http://www.w3.org/2001/XMLSchema#string

Mei Yieng Chin

http://www.w3.org/2001/XMLSchema#string

Steven Pham

http://www.w3.org/2001/XMLSchema#string

P2860

Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer

Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention.

Androgen receptor and its splice variants in prostate cancer

Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer.

LNCaP model of human prostatic carcinoma.

Limited expression of cytochrome p450 17α-hydroxylase/17,20-lyase in prostate cancer cell lines

Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone.

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.

P304

343

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/CANCERS10100343

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Subrata Deb

P577

2018-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30241348

http://www.w3.org/2001/XMLSchema#string

P921

cancer research

P932

6210088

http://www.w3.org/2001/XMLSchema#string